BRIEF published on 11/04/2025 at 11:35, 3 months 9 days ago Advicenne submits Sibnayal® to the US FDA FDA Advicenna Sibnayal® Renal Tubular Acidosis Registration Filing
PRESS RELEASE published on 11/04/2025 at 11:30, 3 months 9 days ago Informations privilégiées / Autres communiqués Advicenne dépose le dossier d'enregistrement de Sibnayal® auprès de la FDA américaine pour le traitement de l'ATRd. Webconférence le 5 novembre 2025. Informations sur ADV7103 et le développement clinique FDA Advicenne Webconférence ATRd Sibnayal
PRESS RELEASE published on 11/04/2025 at 11:30, 3 months 9 days ago Inside Information / Other news releases Advicenne submits registration application for Sibnayal® in dRTA treatment to US FDA, designated orphan drug. Evaluation process expected to take 12 months Advicenne Sibnayal® US FDA DRTA Treatment Registration Application
BRIEF published on 09/19/2025 at 18:05, 4 months 24 days ago Advicenne: Half-year results in 2025 and outlook Financial Results Outlook Turnover United States Sibnayal®
BRIEF published on 09/19/2025 at 18:05, 4 months 24 days ago Advicenne : Résultats semestriels en 2025 et perspectives Chiffre D'affaires Résultats Financiers Perspectives États-Unis Sibnayal®
PRESS RELEASE published on 09/19/2025 at 18:00, 4 months 24 days ago Informations privilégiées / Communiqué sur comptes, résultats Advicenne présente ses résultats financiers semestriels au 30 juin 2025 et fait le point sur ses activités. Augmentation du chiffre d'affaires et perspectives favorables avec Sibnayal® Résultats Financiers Croissance Perspectives Advicenne Sibnayal®
BRIEF published on 07/28/2025 at 07:35, 6 months 16 days ago Advicenne Secures Marketing Authorization for Sibnayal® in Saudi Arabia Saudi Arabia Advicenne Reimbursement Sibnayal® DRTA
BRIEF published on 07/28/2025 at 07:35, 6 months 16 days ago Advicenne obtient l'autorisation de mise sur le marché de Sibnayal® en Arabie saoudite Arabie Saoudite Remboursement Advicenne ATRd Sibnayal®
PRESS RELEASE published on 07/28/2025 at 07:30, 6 months 16 days ago Informations privilégiées / Autres communiqués Advicenne obtient l’AMM et le remboursement de Sibnayal en Arabie Saoudite pour le traitement des maladies rénales rares. Collaboration avec Taïba Healthcare Arabie Saoudite Advicenne Maladies Rénales Rares AMM Sibnayal
PRESS RELEASE published on 07/28/2025 at 07:30, 6 months 16 days ago Inside Information / Other news releases Advicenne obtains marketing authorization and reimbursement for Sibnayal® in Saudi Arabia, a fixed combination for rare kidney diseases, in collaboration with Taïba Healthcare Saudi Arabia Advicenne Reimbursement Marketing Authorization Sibnayal
Published on 02/13/2026 at 17:45, 26 minutes ago Eldorado Gold Closes $2.4 Million Strategic Investment in Gemdale Gold
Published on 02/13/2026 at 14:35, 3 hours 36 minutes ago Datametrex Received $500,000 Purchase Order For Data Centre Solutions
Published on 02/13/2026 at 14:30, 3 hours 41 minutes ago Golden Harp Resources Inc. Receives TSXV Final Acceptance and Closes Acquisition to Create District-Scale Copper Hill Land Package
Published on 02/13/2026 at 14:00, 4 hours 11 minutes ago Troubadour Resources Reports Assay Results from Drill Program at Senneville Gold-Silver-Copper Property
Published on 02/13/2026 at 13:37, 4 hours 34 minutes ago Atlas Salt Expands Strategic MOU with Sandvik Mining Supporting $132 Million of Equipment and Services at Great Atlantic Salt Project
Published on 02/13/2026 at 18:07, 3 minutes ago EQS-Adhoc: Delticom AG: Based on preliminary, unaudited figures for the FY 2025, full-year revenues are below the forecast, while operating EBITDA is expected to be at the upper end of the forecasted range
Published on 02/13/2026 at 17:58, 12 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/13/2026 at 17:45, 25 minutes ago Turkiye Garanti Bankasi A.S.: Redemption of the debt instrument at abroad within the Medium Term Note (MTN) program
Published on 02/13/2026 at 17:45, 26 minutes ago Branicks Group AG: Extraordinary General Meeting approves all items on the agenda
Published on 02/13/2026 at 18:05, 6 minutes ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/01/2026
Published on 02/13/2026 at 18:05, 6 minutes ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/01/2026
Published on 02/13/2026 at 17:50, 21 minutes ago Number of shares and voting rights - January 2026 (In French only)
Published on 02/13/2026 at 17:50, 21 minutes ago Nombre total d'actions et droits de vote - janvier 2026
Published on 02/13/2026 at 17:34, 36 minutes ago Déclaration des transactions sur actions propres réalisées du 02/02/2026 au 06/02/2026
